JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trujillo, M.
Right arrow Articles by Pinto, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trujillo, M.
Right arrow Articles by Pinto, F. M.

Vol. 296, Issue 3, 841-848, March 2001


Hormonal Regulation of the Contractile Response Induced by Okadaic Acid in the Rat Uterus

Mar Trujillo, Luz Candenas, Cristina G. Cintado, Josefina Magraner, Javier Fernandez, Julio D. Martín and Francisco M. Pinto

Institute of Chemical Research, Scientific Research Center Isla de La Cartuja, Sevilla, Spain (M.T., L.C., C.G.C., J.M., J.D.M., F.M.P.); and Institute of Bio-Organic Research, University of la Laguna, Tenerife, Spain (J.F.)

    Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The contractile effect of okadaic acid (OA), a highly selective inhibitor of protein serine/threonine phosphatases, was analyzed in the rat uterus during the estrous cycle and during the course of pregnancy. Contractile effects were related to circulating levels of estrogen and progesterone and to mRNA levels of myosin light chain kinase (MLCK) and of myosin light chain protein phosphatase catalytic (PP1-delta ) and larger regulatory subunit (MYPT). Both in nonpregnant and pregnant uteri, OA (20 µM) induced a transient contraction, which after plateauing, slowly decreased. In the nonpregnant uterus, the amplitude of this contraction varied at different stages of the estrous cycle, being higher at proestrus and lower at diestrus. In the pregnant uterus, the contraction to OA increased significantly during the course of pregnancy, reaching a maximum in day 21 pregnant rats, and declined after delivery. Whatever the day of pregnancy, the amplitude of the contraction to OA was not significantly modified when obtained in Ca2+-free solution. The magnitude of the OA-induced contraction in spontaneously cycling and pregnant rats was positively correlated to the ratio of estrogen/progesterone serum levels. Reverse transcription-polymerase chain reaction assays on myometrial tissue demonstrated that mRNA expression of PP1-delta and MYPT was higher at early (day 3) than at late (day 21) pregnancy. MLCK mRNA levels were similar in day 3 and day 21 pregnant rats. These data suggest that changes in the expression and activity of myosin phosphatase may contribute to modulating the level of uterine contractile force during the estrous cycle, pregnancy, and labor.

    Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

It has long been recognized that the link between excitation at the plasma membrane and smooth muscle contraction is the rise in the intracellular free Ca2+ level, [Ca2+]i (Somlyo and Somlyo, 1994; Horowitz et al., 1996). As a consequence of its elevated concentration, Ca2+ binds to calmodulin, leading to its activation and the subsequent interaction with a number of target proteins, including MLCK (Adelstein and Klee, 1981; Horowitz et al., 1996). Phosphorylation of the 20-kDa myosin light chain (LC20) by MLCK is considered the final and essential step to initiate contraction (Mackenzie et al., 1990; Somlyo and Somlyo, 1994). Relaxation occurs when myosin is dephosphorylated by MLCPP. A multisubunit myosin phosphatase has been isolated from different tissues (Chen et al., 1994; Shimizu et al., 1994; Shirazi et al., 1994). The holoenzyme is trimeric and consists of the delta -isoform of type 1 protein serine/threonine phosphatase (PP1-delta ) and two regulatory subunits. The myosin phosphatase target (MYPT) is a 110- to 130-kDa protein that binds to both PP1-delta and phosphorylated myosin (Chen et al., 1994; Shimizu et al., 1994; Hartshorne and Hirano, 1999). The second regulatory protein (M20) has an apparent molecular mass of 20 to 21 kDa and also appears to bind to MYPT (Hartshorne and Hirano, 1999).

Protein phosphatase inhibitors have been crucial for recent advances in our understanding of smooth muscle contractility (Bialojan et al., 1988; Gong et al., 1992). Among them, OA, a polyether derivative responsible for diarrhetic shellfish poisoning, was the first known inhibitor of protein serine/threonine phosphatases of the PPP family (Takai et al., 1987; Cohen et al., 1990) and these enzymes appear to be the only cellular target of the toxin (Cohen et al., 1990; Schönthal, 1998). The effects of OA are usually attributed to inhibition of PP1 and PP2A, which are thought to be the dominant phosphatases in vivo and account for approximately 90% of cellular PSP activity (Cohen et al., 1990; Schönthal, 1998). Experiments on smooth muscle have shown that OA and other PSP inhibitors caused a contraction that was highly resistant to the absence of extracellular Ca2+ (Obara et al., 1989; Gong et al., 1992) and was accompanied by little or no increase in [Ca2+]i (Ozaki et al., 1987; Hirano et al., 1989). OA induced phosphorylation of LC20 and inhibited dephosphorylation of phosphorylated LC20 in all smooth muscles that have been studied (Bialojan et al., 1988; Erdödi et al., 1988; Obara et al., 1989; Gong et al., 1992). In parallel, experiments in vascular and visceral smooth muscles demonstrated that agonists that activate G protein-coupled membrane receptors were able to develop a higher level of force at a given intracellular level of [Ca2+]i than simple membrane depolarization (Somlyo and Somlyo, 1994). These data have been essential to observe that Ca2+/force relationships are not invariable but depend on the balance between MLCK and MLCPP activities. Therefore, mechanisms that interfere with the activities of the phosphorylating (MLCK) and dephosphorylating (MLCPP) enzymes are able to modulate the level of force and LC20 phosphorylation achieved at a constant [Ca2+]i (Kubota et al., 1992; Gong et al., 1995).

Pregnancy is associated with important changes in electrical and metabolic properties of uterine smooth muscle (Lefebvre et al., 1992; Wray, 1993; Garfield, 1994; Mershon et al., 1994; Tezuka et al., 1995; Pinto et al., 2000). In spite of recent advances in our understanding of the regulation and physiological functions of contractile proteins in smooth muscle, relatively little information exists on the mechanisms of adaptation of uterine smooth muscle during pregnancy. There are conflicting reports suggesting that mechanical activity may (Izumi, 1985) or may not change (Munns and Pennefather, 1998). In the estrogen (E2)-primed rat uterus, we have previously shown that OA induces a contraction that is independent of neurotransmitter release and membrane receptor activation (Candenas et al., 1992, 1994) and depends on a direct interaction with MLCPP (Arteche et al., 1997). The contraction is only slightly reduced in Ca2+-free medium (Candenas et al., 1994) and is not accompanied by changes in [Ca2+]i (Arteche et al., 1997). In the present study, we examined the contractile response elicited by OA in the rat uterus during pregnancy and in the nonpregnant rat uterus at different stages of the estrous cycle and under different hormonal conditions. Serum levels of E2 and P4 were measured by radioimmunoassay, in an attempt to correlate ovarian hormone levels with OA functional activity. In addition, mRNA expression levels of PP1-delta , MYPT, and MLCK were analyzed by RT-PCR on uteri from early (day 3) and late (day 21) pregnant rats.

    Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Animals and Tissue Preparation. All experiments were conducted in accordance with National Institutes of Health guidelines for the care and use of laboratory animals. Three-month-old virgin female Wistar rats were purchased from Charles River Laboratories (Criffa, Spain). Animals were maintained in an air conditioned room at 22°C under controlled lighting (12-h light/dark cycle) and provided with food and water ad libitum. Vaginal smears were checked daily and rats with at least two consecutive 4-day estrous cycles were used. Uteri were obtained from rats at different stages of the estrous cycle. Some animals were pretreated with 17beta -estradiol benzoate (E2; 20, 200, or 3000 µg · kg-1; Sigma, St. Louis, MO). The compounds were dissolved in olive oil and injected (i.p., final volume 1 ml · kg-1) 24 h before the experiment. Pregnancy was produced by mating proestrus rats with male rats overnight. The day of gestation when sperm was observed in the vaginal lavage was defined as day 0 of gestation. Parturition usually occurs in the evening of day 21 or the morning of day 22. Uteri were obtained from rats on days 1, 3, 6, 11, 16, and 21 of pregnancy or from day 1 postpartum rats, the day of birth being zero postpartum. A group of day 10 pregnant rats was injected (s.c.) with either RU486 (mifepristone, 10 mg · kg-1, kindly provided by Roussel-Uclaf, Romaineville, France) or vehicle (1 ml · kg-1 olive oil, control rats) and killed on day 11. Both pregnant and nonpregnant rats were killed by decapitation at 10:00 AM. Trunk blood was collected and the uterine horns were rapidly removed, trimmed of surrounding connective tissue, and opened longitudinally. Uteri from pregnant animals were freed of blood, pups, and placenta. The endometrium was carefully scraped with the aid of a binocular microscope. Tissue samples were excised from the longitudinal smooth muscle layer and quickly frozen in liquid nitrogen and stored at -80°C (RT-PCR studies) or used fresh (functional studies).

Tissue Bath Experiments. Strips of longitudinal uterine smooth muscle (8-10 mm in length and 1-2 mm in width) were prepared and mounted in isolated tissue baths containing 4 ml of a physiological salt solution (PSS) of the following composition: 118 mM NaCl, 5.6 mM KCl, 1.9 mM CaCl2, 0.95 mM MgSO4, 1 mM NaH2PO4, 25 mM NaHCO3, and 11 mM glucose. The preparations were bubbled continuously with 95% O2,5% CO2 and warmed to 37°C. Mechanical responses were recorded isometrically by means of force-displacement transducers (Grass FT-03) connected to a LETICA amplifier and an ABB GOERZ SE 130 multichannel recorder. The tissue was immersed in PSS and equilibrated for 45 min (with changes in bath fluid every 15 min) under a resting tension of 0.5 g. After the equilibration period, the preparation was challenged twice by administration of a maximally effective concentration of acetylcholine (ACh, 1 mM). Uterine strips were then allowed to equilibrate for a further 60-min period before addition of OA (5-20 µM, obtained in Instituto de Bio-Organica, Universidad de la Laguna, Tenerife, Spain; Arteche et al., 1997). Only one concentration of OA was applied to each strip since we found in previous experiments that the polyether cannot be removed by washing (Candenas et al., 1992). Some experiments were carried out in a Ca2+-free medium, prepared by omitting Ca2+ from PSS and adding EGTA (3 mM). At the end of the experiment, each tissue was blotted and dried at 60°C during 24 h. The maximal contractile effect (Emax) induced by OA was expressed in milligrams of contraction (developed from the tension level before OA), as the ratio of milligrams of contraction to milligrams of dry weight, or as a percentage of the maximal contraction evoked by 1 mM ACh. Other parameters obtained for characterizing the biphasic response to OA (time for 50% contraction, time to peak tension, and time for 50% relaxation) were calculated by considering the maximal contraction induced by OA as 100%.

Serum Steroid Levels. Trunk blood was allowed to clot at 4°C. The clotted blood was centrifuged at 2000g for 15 min. Sera were collected, frozen, and stored at -80°C until analysis. Serum concentrations of E2 and P4 were measured by using double-antibody radioimmunoassay kits (DRG Instruments, Marburg, Germany), following instructions by the manufacturer. Both assays used 125I-labeled tracers.

RNA Isolation. Total RNA of approximately 20 mg of rat uterine tissue was isolated according to the acid guanidium isothyocianate-phenol-chloroform extraction method (Chomczynski and Sacchi, 1987) as previously described (Magraner et al., 1998). The RNA samples were treated with fast protein liquid chromatography pure DNase I (Amersham Pharmacia Biotech, Uppsala, Sweden) in DNase buffer (40 mM Tris-HCl, pH 7.5, 6 mM MgCl2) containing 10 units of RNasin (Promega, Madison, WI) to eliminate contaminating genomic DNA. The integrity of the purified RNA was confirmed by visualization of the 28S and 18S ribosomal RNA bands after the electrophoresis of RNA through a 1% agarose-formaldehyde gel. The quantity of total RNA was determined by spectrophotometric measurement at 260 nM. RNA samples (10 µg each) were resuspended in diethylpyrocarbonate-treated water and stored at -80°C until use.

RT-PCR. RT-PCR reactions were carried out as previously described (Pinto et al., 1999). First-strand cDNA was synthesized using Moloney murine leukemia virus reverse transcriptase and random hexamers according to Amersham Pharmacia Biotech instructions (First-Strand cDNA Synthesis kit; Amersham Pharmacia Biotech) in a 15-µl volume reaction containing 5 µg of DNase-treated total RNA. The resulting cDNA samples were amplified by polymerase chain reaction (PCR) using a DNA thermal cycler (MJ Research, Watertown, MA) and the following specific primer pairs: 1) PP1-delta isoform, forward 5'-AACCATGAGTGTGCTAGCATCA-3' and reverse 5'-CACCAGCATTGTCAAA-CTCGCC-3', correspond to nucleotides 411 to 432 and 861 to 882, respectively, based on the published cDNA sequence of the rat PP1-delta (or beta ) isoform (Sasaki et al., 1990) and were designed to amplify a PCR product of 472 bp; 2) MYPT, forward 5'-GACTCCTTGCTGGGTCGTTC-3' and reverse 5'-AGGCCCCATTTTCATCCTTT-3', correspond to nucleotides 2632 to 2651 and 2969 to 2989, respectively, of MYPT cDNA from rat aorta (Chen et al., 1994), giving a PCR product of 358 bp; and 3) MLCK, forward 5'-GGAAGACTGTCA/TTCC/TATGGC-3' and reverse 5'-TTGCAGGTGTAC/TTT-GGCATC-3'. Degenerated primers were designed to amplify rat uterine MLCK, based on the cDNA sequence of human MLCK from hippocampus (Potier et al., 1995). Amplification of the rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene transcript was used to control the efficiency of RT-PCR among the samples. Sequences of forward and reverse primers for GAPDH were 5'-CTACCCACGGCAAGTTCAAT-3' and 5'-CTTCTGAGTGGCAGTGATGG-3', respectively, corresponding to nucleotide position 176 to 195 and 563 to 582, respectively, of the rat GADPH cDNA sequence (Tso et al., 1985). The expected size of the PCR product was 404 bp.

PCR mixes contained 0.2 µM primers, 1.5 U of Taq polymerase (Amersham Pharmacia Biotech), the buffer supplied, 2.5 mM MgCl2, 200 µM dNTPs, and cDNA in 25 µl. Each experiment also contained two negative controls, one with the RT reaction containing no added RNA and the other one containing RNA that had not been reverse transcribed. Following heating at 94°C for 2 min, the parameters used for PCR amplification were as follows: denaturation, 10 s at 94°C; annealing, 20 s at 60°C (for PP1-delta , MLCK, and GADPH) or 20 s at 64°C (for MYPT); and extension, 30 s at 72°C. Cycle numbers were 28 for PP1-delta and GAPDH and 30 for MLCK and MYPT. Number of cycles for each PCR product was chosen from preliminary experiments in which PCR reactions were performed at a serially incremented number of cycles, until linear detection of products. The products of the amplification were separated by gel electrophoresis on 1.7% agarose, stained with ethidium bromide, and visualized andphotographed under UV transilluminator (Spectronics Corp., Rochester, NY).

A semiquantitative RT-PCR assay was used to determine the relative concentrations of PP1-delta , MYPT, and MLCK in uteri from rats at early (day 3) and late (day 21) pregnancy (Bove and Koos, 1993; Pinto et al., 1999). After normalization to GAPDH, equal aliquots of the RT solution for the samples to be compared were serially half diluted and then amplified for a fixed number of cycles, to ensure analysis of products in the exponential range of amplification. PCR products of PP1-delta , MYPT, or MLCK and the correspondent molecular size standard were loaded on the same agarose gel in which GAPDH products and the correspondent molecular size standard were loaded, 30 min ahead. mRNA levels for PP1-delta , MYPT, MLCK, and GAPDH were analyzed on each uterine sample and experiments in each day of pregnancy were carried out in five different animals, with each RT-PCR assay being performed at least in triplicate. The level of expression of each PCR product was normalized to GAPDH mRNA levels and the relative amount of the target sequence in samples from day 21 of pregnancy was expressed as a percentage of the value determined in day 3 pregnant rats. The band intensities were scanned by densitometry using a video documentation system and the image analysis software Intelligent Quantifier (BioImage Systems Corp., Ann Arbor, MI). The identity of the PCR products was established by DNA sequence analysis, as previously described (Pinto et al., 1999).

Statistical Analysis. Values are expressed as the mean ± S.E.M. Unless otherwise indicated, n represents the number of experiments in n different animals. Statistical significance of differences between two means was assessed by Student's t test. Multiple means were compared by one-way analysis of variance followed by Tukey's multiple comparison test (GraphPad Prism 3.0; GraphPad, San Diego, CA). A probability level of P < 0.05 was regarded as significant.

    Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Effects of Okadaic Acid on the Mechanical Activity in the Rat Uterus. OA (5-20 µM) elicited concentration-dependent contraction of the isolated rat uterus. The concentration-response curves obtained in nonpregnant uteri under different hormonal conditions are shown in Fig. 1. OA (>= 5 µM) caused a transient contraction of similar time course in both the pregnant (Fig. 2) and the nonpregnant rat uterus (Figs. 1 and 3). The contraction developed slowly and after plateauing, was followed by a gradual decay in tension (Fig. 2). Due to the limited availability of the toxin and its irreversible effects, a single concentration of OA (20 µM) was used in subsequent experiments.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 1.   Concentration-response curves for OA-induced contraction in the nonpregnant rat uterus at the estrus and diestrus stages of the estrous cycle and in animals treated with E2 (200 µg · kg-1). Data are means ± S.E.M. of three to eight experiments, expressed as a percentage of the contraction to ACh (1 mM).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   Contractile response induced by OA (20 µM) in uteri from early (day 3, black-triangle) and late (day 16, ) pregnant rats. Data are expressed as a percentage of the contraction to ACh (1 mM) (A); as the tension change induced by OA, in milligrams (B); and as the ratio of milligrams of contraction to milligrams of tissue dry weight (C). Each data are the mean ± S.E.M. of five experiments.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 3.   Maximal contractile response induced by OA (20 µM) in uteri from nonpregnant rats at different stages of the ovarian cycle or under different imposed hormonal conditions. Data are means ± S.E.M. of four to eight experiments, expressed as a ratio of milligrams of contraction to milligrams of tissue dry weight. A, maximal amplitude at metestrus (Met.), diestrus (Diest.), proestrus (Proest.), and estrus (Est.). *P < 0.05, significant differences from OA responses at metestrus and diestrus; #P < 0.05, significant differences from OA responses at estrus, one-way analysis of variance. B, maximal amplitude in animals treated with E2 (20, 200, or 3000 µg/kg). dagger P < 0.05, significant differences from OA responses in E2 (3000 µg · kg-1)-treated animals, one-way analysis of variance.

In the nonpregnant rat uterus, the amplitude of the contraction to OA (20 µM) varied at different stages of the estrous cycle following the sequence: proestrus > estrus > diestrus >=  metestrus (Fig. 3A). In rats treated with 17beta -estradiol benzoate (20, 200, or 3000 µg · kg-1), the magnitude of the contraction to OA was directly related to the concentration of E2 administered (Fig. 3B).

In the pregnant uterus, the magnitude of the contraction to OA (20 µM) was low at early pregnancy; increased significantly during the course of pregnancy, reaching a maximum in day 21 pregnant rats; and declined after delivery (Fig. 4). The characteristics of the OA-induced response are shown in Table 1. Whatever the day of pregnancy, the amplitude of the OA-induced contraction was only slightly lower in Ca2+-free, 3 mM EGTA-containing solution than in Ca2+-containing medium. As a representative example, Fig. 5 shows the OA-induced contractile response on day 3 and day 16 of pregnancy, in the presence and in the absence of Ca2+ in the medium. In day 11 pregnant rats, treatment with RU486 (10 mg · kg-1, 24 h before experimentation) caused vaginal bleeding and there was a significant increase in the amplitude of the uterine contraction to OA compared with control (olive oil-treated) day 11 pregnant rats (n = 3 different animals per group; P < 0.05, unpaired t test; Fig. 3; Table 1).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   Time course of the contractile response to OA (20 µM) in uteri from pregnant rats at different stages of pregnancy, in day 1 postpartum and in day 11 pregnant rats pretreated with RU486 (10 mg · kg-1, 24 h before the experiment). black-square, day 1; triangle , day 3; black-down-triangle , day 6; black-diamond , day 11; , day 16; , day 21; black-triangle, after-labor; and down-triangle, RU486. Data are means ± S.E.M. of three to seven experiments, expressed as a ratio of milligrams of contraction to milligrams of tissue dry weight.


                              
View this table:
[in this window]
[in a new window]
 
TABLE 1
Parameters characterizing the contractile response induced by OA (20 µM) in the rat uterus during the course of pregnancy, in day 1 postpartum and in day 11 pregnant rats pretreated with RU486 (10 mg · kg-1) 24 h before the experiment

Values are means ± S.E.M.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   Time course of the contractile response induced by OA (20 µM) in uteri from early (day 3) and late (day 16) pregnant rats in a Ca2+-containing (1.9 mM Ca) and a Ca2+-free solution containing 3 mM EGTA (0 mM Ca). black-triangle, day 3; triangle , day 3 Ca(0); , day 16 Ca(1.9); and open circle , day 16 Ca(0). Data are means ± S.E.M. of five experiments, expressed as a ratio of milligrams of contraction to milligrams of tissue dry weight.

Serum Steroid Levels. Circulating levels of ovarian steroids and the ratio of E2/P4 serum levels in nonpregnant and pregnant (day 3 and day 21) rats are shown in Table 2. As can be observed, the magnitude of the OA-induced contraction in spontaneously cycling, estrogen-treated, and pregnant rats was, in most cases, positively correlated to the ratio of E2/P4 serum levels.


                              
View this table:
[in this window]
[in a new window]
 
TABLE 2
Serum levels of E2 and P4 and E2/P4 ratio of serum levels in nonpregnant rats at different stages of the estrous cycle, in nonpregnant rats treated with E2 (20, 200, or 3000 µg/kg 24 h before the experiment), and in pregnant rats at day 3 and day 21 of pregnancy

Values are means ± S.E.M.

RT-PCR Assays. RT-PCR analysis of uterine mRNA from early (day 3) and late (day 21) pregnant rats revealed the presence of single transcripts corresponding to the sizes expected for PP1-delta (472 bp), MYPT (358 bp), MLCK (380 bp), and GAPDH (404 bp) (Fig. 6). The identity of PCR products was confirmed by determination of DNA nucleotide sequences. In all experiments, the two negative controls yielded no detectable products, indicating that 1) all reagents were free of target sequence contamination, and 2) the RT-PCR products do not come from contaminating genomic DNA.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 6.   Agarose gels showing RT-PCR products for uterine cDNA from day 3 (lanes 1-5) and day 21 (lanes 6-10) pregnant rats. Equal aliquots of the RT solution were serially diluted in a 1:2 ratio and amplified for 28 (PP1-delta and GAPDH) or 30 (MYPT and MLCK) cycles with specific primers for each target sequence. Lanes 1 and 6 represent the more diluted samples in each series. The observation of a steadily declining yield of product at each dilution step confirmed that the comparison of the two samples was made in the exponential portion of the amplification curve. The amount of PP1-delta , MYPT, or MLCK mRNA was then assessed relative to the amount of the coamplified GAPDH fragment. Data represent results in five different animals per day of pregnancy.

A semiquantitative RT-PCR analysis of uterine RNA from day 3 and day 21 pregnant animals was performed to establish whether PP1-delta , MYPT, and MLCK mRNA expression levels varied during the course of pregnancy. Densitometry analysis of PCR products followed by normalization to GAPDH revealed that mRNA expression levels of PP1-delta and MYPT were 2.3- and 2.2-fold higher, respectively, at early (day 3) than at late (day 21) pregnancy (Fig. 7). MLCK mRNA levels were similar on day 3 and day 21 pregnant rats (Fig. 7).


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 7.   PP1-delta , MYPT, and MLCK mRNA levels in uteri from day 3 and day 21 pregnant rats. The relative mRNA level in each tissue was determined as the ratio of PP1-delta , MYPT, or MLCK PCR product/GAPDH PCR product measured by densitometry. After normalization to GAPDH, expression of each mRNA in uteri from day 3 pregnant rats was considered as 100. Each column represents the mean ± S.E.M. of 12 to 21 experiments in five different animals. ***P < 0.001 (significant difference from mRNA levels in pregnancy day 3 rats, paired t test).

    Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The data presented in this article show that the contractile response induced by okadaic acid in the rat uterus is dramatically altered during the course of pregnancy, being significantly higher in late than in early pregnancy. PP1-delta and MYPT mRNA expression levels were higher on pregnancy day 3 than on pregnancy day 21, whereas MLCK mRNA expression was unchanged. These results show that pregnancy is associated with changes in the sensitivity of the rat uterine contractile machinery to MLCPP inhibition. A significant alteration in the magnitude of the OA-induced contraction was also observed in nonpregnant uteri during the oestrous cycle. Moreover, the amplitude of the OA-induced contraction in spontaneously cycling, estrogen-treated and pregnant rats was positively correlated to the ratio of E2/P4 serum levels. These data suggest that, at least in the uterus, ovarian steroids are able to modulate the Ca2+ sensitivity of the contractile machinery.

OA (20 µM) induces a transient contraction of similar time course in uteri from nonpregnant and pregnant rats at all stages of pregnancy. In smooth muscle, the mechanism of action of OA is ascribed to its binding to the catalytic subunit of MLCPP, leading to phosphatase inhibition and then to an increase in the phosphorylation state of LC20 (Bialojan et al., 1988; Obara et al., 1989; Gong et al., 1992). Okadanol, an OA analog that is ineffective as a phosphatase inhibitor (Nishiwaki et al., 1990), failed to contract uterine smooth muscle (Arteche et al., 1997). In the nonpregnant rat uterus, the OA-induced contraction did not involve activation of neurogenic mechanisms or membrane-coupled receptors and was not altered in the presence of various cAMP- and/or cGMP-elevating agents (Candenas et al., 1992). Moreover, the OA-induced response was not dependent on calmodulin and was unaffected by inhibition of protein kinase C, protein kinase A, Ca2+/calmodulin kinase II, phospholipase C, or phospholipase A2 (Arteche et al., 1997). It was also found that the amplitude of the contraction to OA was significantly reduced in the presence of a selective inhibitor of MLCK (Arteche et al., 1997). Taken together, these data suggest that the contractile response induced by OA in the rat uterus is due to a direct interaction with the contractile machinery and appears to be mediated by inhibition of MLCPP. In this connection, it has been shown that OA induces LC20 phosphorylation and inhibited dephosphorylation of phosphorylated LC20 in all smooth muscles that have been studied (Bialojan et al., 1988; Erdödi et al., 1988; Obara et al., 1989; Gong et al., 1992).

In the pregnant rat uterus, it has been shown that L-type calcium channel density increases during the course of pregnancy, being maximal at term, just before labor (Mershon et al., 1994; Tezuka et al., 1995). The present study shows that contractions elicited by OA in uteri from pregnant animals at different stages of pregnancy were only slightly lower in amplitude and less sustained in Ca2+-free 3 mM EGTA than in Ca2+-containing solution. These results are similar to those previously obtained in the nonpregnant rat uterus (Candenas et al., 1994). Moreover, OA (20 µM) failed to alter [Ca2+]i values and had no effect on Ca2+ movements in myometrial cells (Arteche et al., 1997) as also occurs in other tissues (Hirano et al., 1989; Obara et al., 1989). This suggests that L-type Ca2+ channels and the subsequent increase in [Ca2+]i that result from its activation are not responsible for the increase in the amplitude of the response to OA observed during pregnancy.

Smooth muscle contraction is primarily regulated by the phosphorylation state of LC20, which depends on the balance between MLCK and MLCPP activities. We therefore investigated whether MLCK and MLCPP mRNA expression varied during the course of pregnancy. Our results show that MLCK mRNA levels were similar in early (day 3) and late (day 21) pregnant rats. On the other hand, PP1-delta mRNA expression levels were 2-fold higher on pregnancy day 3, compared with pregnancy day 21. These data suggest that changes in MLCPP activity could explain the alterations in the magnitude of the OA-induced contraction observed during pregnancy.

In the cells, protein phosphatases of the PPP family exist as holoenzymes, with the catalytic subunit associated to one or more regulatory proteins (Hartshorne and Hirano, 1999). The association of catalytic subunits with a variety of regulatory proteins generates a diversity of phosphatase holoenzymes that may be targeted to specific substrates and signaling complexes (Oliver and Shenolikar, 1998). At the present moment, it is unknown whether the formation of these holoenzymes is regulated as a function of subunit abundance or as a consequence of catalytic/regulatory protein modification. In addition to the catalytic subunit, PP1-delta , smooth muscle MLCPP is composed of two regulatory subunits (Chen et al., 1994; Hartshorne and Hirano, 1999). The large regulatory subunit MYPT binds to both PP1-delta and phosphorylated myosin and appears to be essential for targeting MLCPP to its substrate, i.e., myosin (Shimizu et al., 1994; Hartshorne and Hirano, 1999). The present study shows that MYPT mRNA expression was about 2-fold higher in day 3 than in day 21 pregnant rats. Although these results do not negate the existence of post-translational regulatory mechanisms, the fact that MYPT mRNA expression varied during the course of pregnancy suggests that regulation of expression levels of subunits could be a way by which the cell regulates the formation of a particular PSP holoenzyme.

The magnitude of the contraction to OA was low at early pregnancy and high at late pregnancy. Our data also show 1) in nonpregnant rats treated with E2, the magnitude of the contraction to OA was directly related to the concentration of E2 administered; 2) the contraction to OA was higher in day 11 pregnant rats pretreated with RU486 than in day 11 control animals; and 3) the amplitude of the contraction to OA in spontaneously cycling, E2-treated and pregnant rats was, in most cases, positively correlated to the ratio of E2/P4 serum levels. This strongly suggests that ovarian steroids are able to modulate the Ca2+ sensitivity of the uterine contractile machinery by regulating MLCPP activity. The lack of positive correlation under certain hormonal conditions, i.e., the estrus and diestrus stages of the ovarian cycle, could suggest that, in addition to E2 and P4, other still unknown factors may also be involved in the regulation of the sensitivity of the uterine contractile machinery.

The uterus must be maintained in a quiescent state during pregnancy and develop important contractions during labor (Wray, 1993). The present data show that, in addition to the important changes in the expression of different membrane receptors, ion channels, gap junctions, and local hormone levels (Lefebvre et al., 1992; Wray, 1993; Garfield, 1994; Mershon et al., 1994; Pinto et al., 2000), the sensitivity of the uterine contractile proteins to protein phosphatase inhibition varied during the course of pregnancy. This is consistent with the observation that the mechanical response elicited by contractile agents in the myometrium is progressively increased during the course of pregnancy (Izumi, 1985). This could at least partially explain the poor effect of most drugs in the treatment of post- or preterm labor.

In conclusion, the present data show that ovarian steroids regulate the magnitude of the contraction to OA in the rat uterus. Changes in the expression and activity of myosin light chain phosphatase may contribute to modulate the level of uterine contractile force during the estrous cycle, pregnancy, and labor.

    Acknowledgment

We are very grateful to Roussel-Uclaf for kind donation of RU486.

    Footnotes

Accepted for publication October 31, 2000.

Received for publication August 1, 2000.

This work was supported by grants from the Ministry of Education and Science (Spain) (PB 97-1123) and from Fundación Ramón Areces (Spain). M.T. is the recipient of a fellowship from Fundación Ramón Areces, Spain. C.G.C. is the recipient of a fellowship from the Ministry of Science, Spain.

Send reprint requests to: Dr. Francisco M. Pinto, Instituto de Investigaciones Químicas, Centro de Investigaciones Científicas Isla de La Cartuja, Avda. Americo Vespucio s/n, 41092 Sevilla, Spain. E-mail: mluz{at}cica.es

    Abbreviations

[Ca2+]i, cytosolic Ca2+ concentration; MLCK, myosin light chain kinase; LC20, 20-kDa myosin light chain; MLCPP, myosin light chain protein phosphatase; PP1-delta , protein phosphatase type 1 delta -isoform; MYPT, large myosin phosphatase target subunit; OA, okadaic acid; PSP, protein serine/threonine phosphatases; E2, 17beta -estradiol; P4, progesterone; RT-PCR, reverse transcription-polymerase chain reaction; PSS, physiological salt solution; ACh, acetylcholine; bp, base pairs; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

    References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References


0022-3565/01/2963-0841-0848$03.00
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Biol. Reprod.Home page
J. N. Pennefather, E. Patak, S. Ziccone, A. Lilley, F. M. Pinto, N. M. Page, M. E. Story, S. Grover, and M. L. Candenas
Regulation of the Stimulant Actions of Neurokinin A and Human Hemokinin-1 on the Human Uterus: A Comparison with Histamine
Biol Reprod, September 1, 2006; 75(3): 334 - 341.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. L. Ribeiro, J. Aisemberg, S. Billi, M. G. Farina, R. Meiss, S. McCann, V. Rettori, M. Villalon, and A. M. Franchi
Epidermal growth factor prevents prepartum luteolysis in the rat
PNAS, May 31, 2005; 102(22): 8048 - 8053.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
E. Patak, F. M. Pinto, M. E. Story, C. O. Pintado, A. Fleming, N. M. Page, J. N. Pennefather, and M. L. Candenas
Functional and Molecular Characterization of Tachykinins and Tachykinin Receptors in the Mouse Uterus
Biol Reprod, May 1, 2005; 72(5): 1125 - 1133.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Xiao and L. Zhang
Adaptation of uterine artery thick- and thin-filament regulatory pathways to pregnancy
Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H142 - H148.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
A. W. Ayres, D. W. Carr, D. S. McConnell, R. W. Lieberman, and G. D. Smith
Expression and Intracellular Localization of Protein Phosphatases 2A and 2B, Protein Kinase A, A-Kinase Anchoring Protein (AKAP79), and Binding of the Regulatory (RII) Subunit of Protein Kinase A to AKAP79 in Human Myometrium
Reproductive Sciences, October 1, 2003; 10(7): 428 - 437.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Xiao, X. Huang, W. J. Pearce, L. D. Longo, and L. Zhang
Effect of cortisol on norepinephrine-mediated contractions in ovine uterine arteries
Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1142 - H1151.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trujillo, M.
Right arrow Articles by Pinto, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trujillo, M.
Right arrow Articles by Pinto, F. M.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews